Efficacy and safety of TNF inhibitors - results of randomized controlled clinical trials
Journal Title: Reumatologia - Year 2006, Vol 44, Issue 6
Abstract
TNF inhibitors were first approved for treatment of active rheumatoid arthritis (RA) in 1998. Since that time, a series of multicentre, randomized controlled trials have been evaluated in early and established RA, in patients who had not been treated with methotrexate (Mtx) as well as in those who had an inadequate response to traditional disease modifying antirheumatic drugs (DMARD), including Mtx. In these trials approximately 6000 RA patients have participated. Clinical response to treatment and adverse effects of anti-TNF agents are discussed. The relative expense of TNF inhibitors makes their universal use impractical. The use of TNF inhibitors in the treatment of active RA should be considered when traditional DMARD, including combination therapy of DMARD, are not effective.
Authors and Affiliations
Anna Filipowicz-Sosnowska
Keywords
Related Articles
- EP ID EP149604
- DOI -
- Views 63
- Downloads 0
The presence of endotoxin in synovial fluids from connective tissue diseases (Ctd-s) patients with as a suspected disease aethiological marker
The aim of the study was to show the presence of endotoxin in the synovial fluids from the patients suffering of Ctd-s (in prevalence RA and other undifferentiated joint arthritis). The usefulness of the applied LAL-tes...
Sarcoidosis
Sarcoidosis is a systemic disorder of unknown origin. It is characterized by a noncaseating granulomatous. Many organs can be affected, but the most frequently lungs (almost 90% cases of sarcoidosis). The other organs: l...
Clinical utility of the anti-cyclic citrullinated peptide assay in choldren with juvenile idiopathic arthritis
Antibodies against cyclic citrullinated peptide (anti-CCP) are considered to be specific for rheumatoid arthritis (RA). Aim: to correlate serum anti-cyclic citrullinated peptide antibody levels with juvenile idiopathic a...
The Twentieth Congress of Russian Internists Centenary of the Russian Scientific Society of Internal Medicine Moscow, December 2-4, 2009
Wczesne wyniki leczenia infliksymabem pacjentów chorych na reumatoidalne zapalenie stawów
Celem pracy była analiza wyników leczenia z użyciem infliksymabu pacjentów z reumatoidalnym zapaleniem stawów (RZS). Analizą objęto 31 chorych (3 mężczyzn, 28 kobiet) w wieku średnio 50 lat (22–67 lat), leczonych w jedny...